Cybin announces promising results from sponsored kernel flow® feasibility study measuring psychedelic effects on the brain

Toronto--( business wire )--cybin inc. (neo:cybn) (nyse american: cybn) (cybin or the company), a biopharmaceutical company focused on progressing psychedelics to therapeutics® today announced key highlights from the completed feasibility study conducted by its partner hi, llc dba kernel (“kernel”), evaluating kernel's flow® wearable technology to measure ketamine's psychedelic effect on cerebral cortex hemodynamics. results from this cybin-sponsored study are intended to inform the future pathway for this program.
CYBN Ratings Summary
CYBN Quant Ranking